Company Overview and News
Americans have started to splurge on discretionary items after a ho-hum winter season. This is well reflected in the pickup in retailers’ March sales, putting an end to three straight months of a decline. Consumer outlays rose on the back of a strong jobs market, rise in income, tax cuts and refunds. Consumer optimism, by the way, continues to remain at a high level.
On Apr 16, the U.S. Commerce Department reported retail sales growth of 0.6% for the month of March reversing the trend of decline in last three consecutive months. The core retail sales also increased in March. This is a major positive since it closely corresponds to the consumer expenditure component of U.S. GDP. Rebound in March retail sales can primarily be attributed to strong performance by auto dealers followed by Internet retailers, pharmacies, restaurants & bars and stores that sell home furnishings.
Dine Brands Global, Inc. (DIN - Free Report) , formerly known as DineEquity, Inc., has partnered with Comcast Business — a subsidiary of Comcast Corporation (CMCSA - Free Report) — to offer outstanding dining experience at its restaurants. At its more than 2,850 locations, Comcast is likely to provide managed services like firewall/router, broadband, switch, WiFi premium and business continuity.
It’s not too terribly difficult to find stocks you want to hold onto indefinitely. Warren Buffett does it all the time; his favorite holding period is “forever.” The opposite exercise isn’t nearly as easy to execute, however. Stocks are inherently intended to rise, and given enough time, most of them do exactly that.
U.S. stocks not only suffered their worst week in more than two years but are also on the brink of logging the worst March. Trump-China trade war rhetoric is threatening global economic growth, while a tighter monetary policy is about to hinder the bull run that began almost a decade ago.
Restaurant Brands International Inc. (QSR - Free Report) is trying all means to cope with a challenging operating environment. To this end, the company is focused on improving its level of service through new product development, comprehensive training, reimaging efforts, attractive menu options and delivery expansion.
Dine Brands Global, Inc. (DIN - Free Report) , formerly known as DineEquity, Inc. is currently a well-performing restaurant stock and its strong fundamentals could ensure a continued bull run.
The Wendy's Company (WEN - Free Report) yesterday announced that it will open a restaurant, Smart 55, at 877 London Blvd, Portsmouth, VA., on Mar 22. The new outlet, to a great extent, will deviate from the earlier Wendy’s restaurants in terms of design and appearance.
Shifting consumer habits and a plethora of new delivery options have left the restaurant industry in flux, with traditional delivery powerhouses like some fast-food pizza chains struggling to compete. One such company is Papa John’s (PZZA - Free Report) .
The Wendy's Company’s (WEN - Free Report) topline is currently under pressure due to the system optimization initiative through franchising. However, initiatives like menu innovation, technological upgrades, international expansion and re-imaging of units are somewhat offsetting the pressure.
BJ’s Restaurants, Inc.’s (BJRI - Free Report) multiple sales boosting and cost-cutting initiatives are impressive. However, rising labor costs amid a tepid sales environment along with a slowdown in the company’s development plans remain potent headwinds.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET